The news: AbbVie is acquiring Apogee Therapeutics, a biotech company developing treatments for inflammatory and immune-mediated diseases, including atopic dermatitis and asthma. The deal is valued at $10.9 billion in cash.

Why it matters: Pharma's dealmaking in the first half of 2026 has already eclipsed all of 2025. The Apogee acquisition is the 33rd biotech buyout valued at $1 billion or more this year, part of a buying frenzy that has pushed total spending by drugmakers and large biotechs to roughly $134 billion, surpassing the 25 such acquisitions worth $112 billion completed last year, per STAT’s tracker. Q1 2026 alone produced the highest pharma deal value since 2020, according to a June PwC report.

Drugmakers are preparing for looming patent cliffs and growing more confident that the worst of regulatory uncertainty is behind them. Annual US branded-drug revenue losses from expiring patents could reach $200 billion to $400 billion by 2030, per estimates from DrugPatentWatch, opening the door to lower-cost generic and biosimilar competition and increasing pressure on large pharma players to develop new products. Meanwhile, drug pricing pressures and tariff threats from the Trump administration persist, but most large pharma companies (including AbbVie) have secured favorable agreements expected to keep revenue impacts manageable, giving them greater clarity to pursue deals.

AbbVie has lived through the patent-cliff math. Humira, once its top-selling therapy, lost its long-standing protection from major biosimilar competition in 2023. Patents for replacement blockbusters Skyrizi and Rinvoq extend into the 2030s, but the company is seeking additional growth catalysts before that clock runs out. Apogee bolsters AbbVie’s category lead with its top candidate, zumilokibart, which is advancing toward Phase 3 trials for atopic dermatitis (a form of eczema), asthma, and other inflammatory diseases

Implications for pharma companies: AbbVie’s strategy underscores a potential split in pharma M&A, While some drugmakers chase high-opportunity markets such as weight loss and oncology, others are doubling down on existing leadership positions. The latter group is betting that deep therapeutic expertise and established physician relationships will yield more predictable returns. Ultimately, it’s a trade-off between diversifying into new revenue streams and maximizing strength where they already excel.

Regardless of strategy, competition for next-generation therapies is driving up deal values and creating favorable conditions for biotech sellers. As large drugmakers use M&A to address pipeline gaps and offset future revenue losses, they are becoming more willing to pay for promising assets. That will increase pressure on acquirers to deliver both clinical milestones and commercial returns.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.